Medinol Was Boston Scientific’s First And Final Pipeline Partner, CFO Vows
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is extracting a painful lesson from its failed business relationship with former stent partner Medinol: never delegate manufacturing and R&D authority to another firm